Bringing Treatments to Patients Faster by Democratizing ClinTech
The Silicon Review talked with Suresh Katta, Saama’s Chairman Emeritus, about using artificial intelligence (AI) and other innovative technologies to reimagine the drug development paradigm.
The wide-ranging interview touched on how disruptive technologies can enhance the development of treatments for rare diseases, bridge gaps created by The Great Resignation, and help pharma and biotech companies achieve scale, acceleration, and repeatability across therapeutic areas.
